Aurobindo Pharma Wins USFDA Approval for Inhalation Aerosol
By ThePip Desk
Aurobindo Pharma secures USFDA approval for its first MDI product, Beclomethasone Dipropionate HFA Inhalation Aerosol, targeting a $301M market.
Breaking Into Complex Respiratory Therapies
Aurobindo Pharma has secured final approval from the US Food and Drug Administration to manufacture and market Beclomethasone Dipropionate HFA Inhalation Aerosol in strengths of 40 mcg and 80 mcg. This product serves as a generic equivalent to QVAR Inhalation Aerosol marketed by Teva Branded Pharmaceutical Products R and D LLC.
This regulatory clearance marks a major operational milestone for the company. Here is what defines the scope of this approval:
- Represents Aurobindo’s first metered-dose inhaler product.
- Expands the company presence into complex respiratory therapies.
- Strengthens capabilities within the inhalation segment.
Manufacturing Strategy and Key Metrics
Production will take place at the company facility located in Raleigh, North Carolina. This site is owned by Aurolife Pharma LLC, which operates as a wholly owned step-down subsidiary of Aurobindo Pharma.
Market intelligence and financial metrics highlight the commercial scale of this regulatory clearance. The core figures connected to this milestone include:
- $301 million estimated US market size for the approved and newer reference products for the twelve months ended July 2026, according to IQVIA data.
- 596 cumulative USFDA ANDA approvals achieved by Aurobindo Pharma.
- 571 final approvals included in the cumulative total.
- 25 tentative approvals making up the remainder of the regulatory count.
Expanding the Differentiated Portfolio
The company operates across multiple segments of the pharmaceutical sector. Its manufacturing capabilities span active pharmaceutical ingredients, intermediates, and generic formulations such as astemizole, domperidone, and omeprazole.
Additional operational focus areas for the enterprise include anti-infectives, oral and sterile antibiotics, pain management, and osteoporosis portfolios. The newly approved inhalation product is scheduled for commercial launch in upcoming quarters, adding to this established range of differentiated products.